Supervivencia global en pacientes con cáncer gástrico avanzado o metastásico en los últimos 10 años en el Centro Médico Nacional «20 de noviembre del ISSSTE»
Denisse Añorve B. , Fernando Aldaco S. , Perla Pérez P. , Laura Torrecillas T. , M. Guadalupe Cervantes S. , Aura A. Erazo Valle Solis , Nora Sobrevilla M. , Alexandro Martínez G. , Raúl Lugo Villegas
{"title":"Supervivencia global en pacientes con cáncer gástrico avanzado o metastásico en los últimos 10 años en el Centro Médico Nacional «20 de noviembre del ISSSTE»","authors":"Denisse Añorve B. , Fernando Aldaco S. , Perla Pérez P. , Laura Torrecillas T. , M. Guadalupe Cervantes S. , Aura A. Erazo Valle Solis , Nora Sobrevilla M. , Alexandro Martínez G. , Raúl Lugo Villegas","doi":"10.1016/j.gamo.2015.12.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The introduction of new drugs for the treatment of patients with advanced, recurrent or metastatic gastric cancer has resulted in a small benefit in overall survival (OS) and progression free survival (PFS).</p></div><div><h3>Objective</h3><p>To determine the impact of new chemotherapy schedules on the OS of patients with advanced or metastic gastric cancer treated at the Centro Medico Nacional 20 de noviembre, ISSSTE.</p></div><div><h3>Material and methodology</h3><p>Retrolective, descriptive study, the clinical files of patients with advanced, recurrent or metastatic gastric cancer treated with chemotherapy at the Centro Medico Nacional 20 de noviembre, ISSSTE, from january 2002 to december 2012, were analyzed. Chemotherapy schedules, OS and PFS were evaluated. Patients were assigned to two cohorts: those treated from january 2002 to december 2006 were included in cohort A and those treated from january 2007 to december 2012 in cohort B. These time periods were determined based on the years when newer chemotherapy agents (anthracyclines, oxaliplatin, capecitabine and docetaxel) were introduced in our institution.</p></div><div><h3>Results</h3><p>291 clinical files were analyzed; 221 patients were excluded for they had clinical stage I, II or resectable III disease, started first line chemotherapy as outpatients of our institution or were not candidates for chemotherapy. 70 cases treated with first line chemotherapy were included. OS for patients in cohort A was 11.2 months vs 10.5 months for patients in cohort B. PFS was 8.5 months vs 5.2, respectively. There was no statistical difference in either comparison.</p></div><div><h3>Conclusion</h3><p>There was no impact of the introduction of newer chemotherapy agents in OS or PFS in patients treated in our institution. A small sample size and the fact that patients with poor performance status received chemotherapy could have had influenced the results of our study, in which tendency towards a better outcome for patients treated with newer chemotherapy schemes was observed, although a statistically significant benefit was not proven.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"14 6","pages":"Pages 313-318"},"PeriodicalIF":0.1000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2015.12.003","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaceta Mexicana de Oncologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665920115001157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Background
The introduction of new drugs for the treatment of patients with advanced, recurrent or metastatic gastric cancer has resulted in a small benefit in overall survival (OS) and progression free survival (PFS).
Objective
To determine the impact of new chemotherapy schedules on the OS of patients with advanced or metastic gastric cancer treated at the Centro Medico Nacional 20 de noviembre, ISSSTE.
Material and methodology
Retrolective, descriptive study, the clinical files of patients with advanced, recurrent or metastatic gastric cancer treated with chemotherapy at the Centro Medico Nacional 20 de noviembre, ISSSTE, from january 2002 to december 2012, were analyzed. Chemotherapy schedules, OS and PFS were evaluated. Patients were assigned to two cohorts: those treated from january 2002 to december 2006 were included in cohort A and those treated from january 2007 to december 2012 in cohort B. These time periods were determined based on the years when newer chemotherapy agents (anthracyclines, oxaliplatin, capecitabine and docetaxel) were introduced in our institution.
Results
291 clinical files were analyzed; 221 patients were excluded for they had clinical stage I, II or resectable III disease, started first line chemotherapy as outpatients of our institution or were not candidates for chemotherapy. 70 cases treated with first line chemotherapy were included. OS for patients in cohort A was 11.2 months vs 10.5 months for patients in cohort B. PFS was 8.5 months vs 5.2, respectively. There was no statistical difference in either comparison.
Conclusion
There was no impact of the introduction of newer chemotherapy agents in OS or PFS in patients treated in our institution. A small sample size and the fact that patients with poor performance status received chemotherapy could have had influenced the results of our study, in which tendency towards a better outcome for patients treated with newer chemotherapy schemes was observed, although a statistically significant benefit was not proven.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
